



# ANUPAM RASAYAN INDIA LTD.

ARILSLDSTX20260523016

Date: May 23, 2026

To, <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001, India.  <b>SCRIP CODE: 543275</b>	To, <b>National Stock Exchange of India Limited</b> 'Exchange Plaza', C-1, Block-G, Bandra Kurla Complex, Bandra (East), Mumbai-400051, India.  <b>SYMBOL: ANURAS</b>
--	---

Dear Sir/Madam,

**Subject: Investor Presentation- Q4 & FY26**

Pursuant to Regulation 30 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the 'Investor Presentation' in respect of the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026, of Anupam Rasayan India Limited (the "Company").

The Investor Presentation will also be hosted on the website of the Company at [www.anupamrasayan.com](http://www.anupamrasayan.com).

We kindly request you to note the same and take into your records.

Thanking you,

Yours Faithfully,

**For Anupam Rasayan India Limited**

**Ashish Gupta**  
Company Secretary & Compliance Officer

Encl: As above



ANUPAM RASAYAN INDIA LTD.

# Anupam Rasayan India Limited

Q4 & FY26

May 2026



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Anupam Rasayan India Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe to any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over-runs on contracts, our ability to manage our international operations, government policies and actions, regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

# 01

Quarterly &  
Full Year  
Highlights



# Highest Ever Annual Performance

## Standalone

Q4FY26

FY26

**₹3,731 Mn**

Y-o-Y growth of **11%**

**₹16,955 Mn**

Y-o-Y growth of **86%**

**₹1,035 Mn**

Y-o-Y de-growth of **7%**

**₹4,252 Mn**

Y-o-Y growth of **53%**

**₹424 Mn**

Y-o-Y growth of **11%**

**₹1,614 Mn**

Y-o-Y growth of **122%**

## Consolidated

Q4FY26

FY26

**₹6,392 Mn**

Y-o-Y growth of **26%**

**₹23,836 Mn**

Y-o-Y growth of **65%**

**₹1,407 Mn**

Y-o-Y de-growth of **6%**

**₹5,430 Mn**

Y-o-Y growth of **32%**

**₹560 Mn**

Y-o-Y de-growth of **11%**

**₹2,222 Mn**

Y-o-Y growth of **39%**

**Total Revenue**

**EBITDA**

**Profit After Tax**

- During the year, the Company successfully concluded the acquisition of Jayhawk Fine Chemicals, marking a significant milestone in its journey toward building a globally integrated specialty chemicals and CDMO platform. Jayhawk delivered strong proforma annual performance, reinforcing the strategic value of the acquisition and significantly strengthening Anupam Rasayan's global manufacturing footprint, advanced chemistry capabilities, and presence in high-value chemistries.
- Added multiple new multinational customers and expanded product portfolio with 3 new product additions during FY26, strengthening the Company's presence across high-value specialty chemical segments.
- Signed a definitive agreement to acquire 43.3-48.2% +Open Offer to the public shareholders of Bliss GVS Pharma which marks a significant step towards expanding capabilities in the pharmaceutical value chain, with strong potential synergies across CDMO capabilities, customer relationships, product development, and global market access.
- Delivered highest-ever operating cash flow of ₹3,343 Mn during the year, reflecting improved business scale, operational efficiency, and stronger cash generation.
- Achieved highest-ever annual sales of ₹ 23,836 Mn, driven by robust execution, new product commercialization, and healthy traction across key business verticals.
- Successfully launched 3 new products during the year, further enhancing the Company's specialty and performance-driven product portfolio.
- Well-positioned for the next phase of growth, supported by increasing contribution from Performance Materials and Pharmaceuticals, backed by strong customer engagement and expanding global opportunities.

**Mr. Anand S Desai**  
MANAGING DIRECTOR

"We are pleased to share that FY26 has been a landmark year for Anupam Rasayan, marked by strong operational execution, strategic expansion, and continued progress toward building a globally integrated specialty chemicals and CDMO platform. During the year, the Company achieved its highest-ever annual sales and operating cash flow performance, reflecting robust business momentum, operational efficiency, and strong cash generation. Growth was driven by commercialization of new products, addition of new multinational customers, and expanding engagements across key business verticals.

We continue to strengthen our presence in niche and complex chemistries where technical expertise and long qualification cycles create strong entry barriers and sustainable growth opportunities.

A key strategic milestone during the year was the successful acquisition of Jayhawk Fine Chemicals in the United States. Jayhawk delivered strong proforma revenue of US\$ 76Mn, reinforcing the strategic value of the acquisition and strengthening our global manufacturing footprint, advanced chemistry capabilities, and integrated CDMO platform. The acquisition also enhances our access to regulated markets and innovator customers across North America.

Additionally, we have signed a definitive agreement to acquire controlling stake in Bliss GVS Pharma which will further strengthen our pharmaceutical value chain capabilities and is expected to create meaningful synergies across CDMO capabilities, product portfolio, and customer relationships.

Looking ahead, we remain well-positioned for the next phase of growth, supported by increasing contribution from Performance Materials and Pharma segment, a strong product pipeline, and expanding global customer engagements."



# Consolidated Quarterly & Full Year Profit & Loss

Particulars (₹ Mn)	Q4FY26	Q4FY25	YoY	FY26	FY25	YoY
Revenue from Operations	6,358	5,002		23,655	14,370	
Other Income	34	55		182	115	
<b>Total Income</b>	<b>6,392</b>	<b>5057</b>	<b>26%</b>	<b>23,836</b>	<b>14,485</b>	<b>65%</b>
Cost of materials consumed	3,315	2,375		13,233	6,045	
Employee Expenses	308	184		866	736	
Other Expenses	1,362	998		4,308	3,580	
<b>EBITDA</b>	<b>1,407</b>	<b>1,500</b>	<b>-6%</b>	<b>5,430</b>	<b>4,123</b>	<b>32%</b>
<b>EBITDA Margin (%)</b>	<b>22%</b>	<b>30%</b>		<b>23%</b>	<b>28%</b>	
Depreciation	427	307		1,399	1,023	
<b>EBIT</b>	<b>980</b>	<b>1,193</b>		<b>4,031</b>	<b>3,101</b>	
Finance Cost	419	312		1,487	1,122	
<b>Profit before Tax</b>	<b>561</b>	<b>881</b>		<b>2,544</b>	<b>1,979</b>	
Tax	1	252		322	379	
<b>Profit After Tax</b>	<b>560</b>	<b>629</b>	<b>-11%</b>	<b>2,222</b>	<b>1,600</b>	<b>39%</b>
<b>PAT Margin (%)</b>	<b>9%</b>	<b>12%</b>		<b>9%</b>	<b>11%</b>	
EPS	3.75	4.06		15.09	8.50	

# Consolidated Balance Sheet

Assets (₹ Mn)	Mar-26	Mar-25
<b>Non Current Asset</b>	<b>42,851</b>	<b>26,959</b>
Net Fixed Asset	38,272	24,007
Financial Assets	1,529	1,364
Other Non-current assets	3,050	1,588
<b>Current Asset</b>	<b>37,275</b>	<b>25,729</b>
Inventories	17,748	14,515
Trade Receivables	9,594	7,338
Cash and Cash Equivalent	3,936	1,277
Other current assets	5,997	2,600
<b>Total</b>	<b>80,126</b>	<b>52,689</b>

Equity & Liabilities (₹ Mn)	Mar-26	Mar-25
<b>Shareholders' Funds</b>	<b>33,338</b>	<b>28,503</b>
Non Controlling Interest	12,962	2,313
<b>Non Current Liabilities</b>	<b>7,672</b>	<b>3,790</b>
Long-Term Borrowings	5,108	1,712
Lease Liability	486	518
Other long-term liabilities	2,078	1,560
<b>Current Liabilities</b>	<b>26,154</b>	<b>18,082</b>
Short-term Borrowings	13,038	11,466
Lease Liability	43	38
Trade Payables	9,455	5,764
Other current liabilities	3,618	814
<b>Total Liabilities</b>	<b>80,126</b>	<b>52,689</b>

# Consolidated Cash Flow Statement


Particulars (₹ Mn)	Mar-26	Mar-25
<b>Net Profit Before Tax</b>	<b>2,544</b>	<b>1,979</b>
Adjustments for: Non -Cash Items / Other Investment or Financial Items	2,957	2,065
<b>Operating profit before working capital changes</b>	<b>5,501</b>	<b>4,044</b>
Changes in working capital	-1,707	-3,917
<b>Cash generated from Operations</b>	<b>3,794</b>	<b>126</b>
Direct taxes paid (net of refund)	-450	-428
<b>Net Cash from Operating Activities</b>	<b>3,343</b>	<b>-301</b>
<b>Net Cash from Investing Activities</b>	<b>-8,202</b>	<b>-3,299</b>
<b>Net Cash from Financing Activities</b>	<b>6,209</b>	<b>2,233</b>
<b>Net Increase/Decrease in Cash and Cash equivalents</b>	<b>1,350</b>	<b>-1,368</b>
Add: Cash & Cash equivalents at the beginning of the period	2,431	2,498
<b>Cash &amp; Cash equivalents at the end of the period</b>	<b>3,781</b>	<b>1,130</b>

# 02


Business  
Overview




# Leading Custom Synthesis Manufacturer




**4 Decades**  
of strong track record




**Backward Integrated**  
Fluorination Player with Strong Supply Chain



**8**  
State of the Art Manufacturing Plants



**2,00,000+ MT**  
Total Manufacturing Capacity



**125+ Products**  
Complex products with 90+ in pipeline



**185+ Clients**  
Including MNCs



**90+**  
Strong R&D Team of Professionals



**2,500+**  
Committed Employees

**Fastest growing Specialty Chemical Manufacturer with focus on Custom Synthesis.**

**Longstanding relationships with leading MNCs**

**Leveraging deep expertise across complex chemistries**

**Building platforms across business verticals of Agro, Personal Care, Pharma and Performance Materials**

On track to achieve **best-in-class ESG standards by 2028**



**Energy net zero** by 2028 on Scope 1+2 emissions

**Consolidated Financials**  
(As per FY26)

**Revenue**  
₹ 23,836 Mn

**EBITDA**  
₹ 5,430 Mn (23%)

**PAT**  
₹ 2,222 Mn (9%)

## PHASE I- INCEPTION


- 1984**  
Formed partnership firm "Anupam Rasayan"
- 2006**  
Started supplying Anti-Bacterial products for German MNC
- 2010**  
Started supplying to Syngenta
- 2014**  
Commercialized large scale manufacturing site - Unit 4

## PHASE II- BUILD UP

- 2016**  
Awarded 'Green Innovation Award' by Corning Reactor Technology
- 2017**  
Started supplying to Sumitomo Japan
- 2019**  
Commercialized 2 more manufacturing sites – Unit 5 & 6
- 2020**  
Received DSIR registration for R&D Centre

## PHASE III- THE ACCELERATION

- 2021**
  - Started working with Adama
  - Listed on NSE and BSE
  - Commissioned Solar Power Plant of 12.5MW at Bharuch
- 2022**
  - Acquired ~26% controlling stake in **Tanfacs Industries Ltd.**
- 2023**
  - Raised ₹5,000 mn. through QIP
  - Commissioned Solar Power Plant of 5.4MW at Bharuch
- 2024**
  - Raised ₹5,500 mn. through Preferential Issue
  - Commissioned Hybrid Power Plant of 9.6MW
- 2025**
  - Signed definitive agreement to acquire U.S. based **Jayhawk Fine Chemicals Corporation**



## Business Verticals Overview

### 1. Life Science Related Specialty Chemicals

#### a. Agrochemicals (including Crop Protection)

Manufacturing agro intermediates and agro active ingredients (insecticides, fungicides and herbicides)

#### b. Personal Care

Manufacturing anti-bacterial and ultraviolet protection intermediates and ingredient

#### c. Pharmaceuticals

Developing intermediates and key starting materials (KSMs) for APIs, material sciences and surface chemistry

Contributes  
**82%\***  
of revenues

### 2. Performance Materials


#### a. Polymer

Manufacturing specialty monomers, ionomers, and oligomers, including high-performance materials for defense, aerospace, and semiconductor applications, utilizing anhydrous hydrogen fluoride across both fluorinated and non-fluorinated chemistries

#### b. Electronic Chemicals

Manufacturing niche molecules for the electronics ecosystem, offering high-quality, low metal content advanced materials used in display chemicals, heat transfer fluids, and AR/VR applications, along with solutions for frontend and backend semiconductor processes, including organic and inorganic fluoride-based battery chemicals.


Contributes  
**18%\***  
of revenues



**125+ Products**

Complex products with 90+ in pipeline

### Business Verticals-Wise Revenue



### Few Top Global Clientele

**syngenta**

**DUPONT**



SUMITOMO CHEMICAL

Nissei Corporation

Note:

- Standalone Figures

- Financials, revenue from operations proportion rounded-off to zero decimal also \*as of FY26.

# State of the Art Manufacturing Facilities

 **8**  
Manufacturing Plants\*

 **2,500+**  
Employees

 **Equipped with  
Pilot Plant Facility**

 **Strategically located  
Near Hazira Port**

## Certifications




- ▶ **Glass-lined, titanium clad stainless-steel reactors** enabling diverse range of products
- ▶ **State-of-the-art infrastructure**, including Continuous flow Silicon carbide and glass reactors (Corning G1 and G4)
- ▶ **World class quality control** system with continuous improvement

Location	Units	Installed Capacity (In MT)
<b>Anupam Rasayan</b>		
Sachin, Gujarat	Unit 1	5,202
	Unit 2	2,520
	Unit 3	6,190
	Unit 6	2,487
Jhagadia, Gujarat	Unit 4	5,425
	Unit 5	8,028
<b>Tanfac Industries</b>		
Cuddalore, Tamil Nadu	Sulphuric Acid	1,00,000
	Hydrofluoric Acid	29,700
	Specialty Fluorides	5,000
<b>Jayhawk Fine Chemicals</b>		
Kansas, U.S	Unit 1	36,000
<b>Total</b>		<b>2,00,552</b>

\*Includes Tanfac and Jayhawk Facilities

# Strong Manufacturing Footprint – India and USA



-  R&D Centre (4)
-  Production Sites
-  Subsidiary

**14+**  
Countries Exports presence

## 8 Manufacturing Facilities

- 4 Plants in Sachin, Gujarat
- 2 Plants in Jhagadia, Gujarat
- 1 Plant in Cuddalore, Tamil Nadu
- 1 Plant in Kansas, US


## 5 Sales Offices

- India
- Japan
- Switzerland
- USA
- UAE

## 4 R&D Centers

- Sachin, Gujarat
- Jhagadia, Gujarat
- Tanfac
- Jayhawk

## 90+ Molecules Under Development



## Deep expertise in complex chemistries

Etherification	Chlorination	Bromination	Sandmeyer
Esterification	Diazotization & Hydrolysis	Condensation	Acylation
Amination	Vilsmeier Haack	Aminolysis	Oxidation
Nitration	Pinner Reaction	Hydrogenation	Fluorination

## Process Technologies

### Flow Chemistry

- ▶ Reduced lead time
- ▶ Material efficient & cost benefits
- ▶ Lesser environmental impacts in the laboratory



### Photo Chemistry

- ▶ Simplified synthesis of complex molecules
- ▶ Larger potential for automation
- ▶ Increased access to novel compounds




## R&D Engine



**90+** Experienced R&D team members with **10% PhDs** and **75+ chemical engineers**



**50 new products** launched from FY20



**2** modern and dedicated DSIR-recognized R&D facilities



**Mr. Anand S Desai**  
MANAGING DIRECTOR

Over 30 years of experience in chemicals industry associated with company since 1992 & was one of first Directors of company



**Mrs. Mona A Desai**  
VICE-CHAIRMAN & WHOLE-TIME DIRECTOR

Over 20 years of experience in chemicals industry and associated with the Board since the incorporation of the company



**Mr. Gopal Agrawal**  
CHIEF EXECUTIVE OFFICER

Qualified CA with 25+ yrs. Exp in Corporate Strategy, global M&A and Mgmt Consultancy. Former MD & Head - IB at Edelweiss India



**Mr. Ravi Desai**  
SALES HEAD

15+ years of experience in sales; with ARIL for ~12 years



**Mr. Amit Khurana**  
CHIEF FINANCIAL OFFICER

Qualified CA with 13+ yrs. exp in taxes/accounts; Former Head of Indirect Taxes & Costing of co., with ARIL for ~10years



**Mr. Vishal Thakkar**  
DEPUTY CFO

22+ yrs. exp. in M&A, BD, contract mgmt. with Shell, Essar, GE Capital, Crisil



**Dr. Nileshkumar Naik**  
TECHNICAL HEAD

PhD (Chem), M.Sc. (Organic chemistry); with ARIL since incorporation



**Dr. Anuj Thakar**  
WHOLE TIME DIRECTOR AND R&D HEAD

PhD (Chem), M.Sc. (Organic chemistry); with ARIL for ~18 yrs.

# 03

Moving up the  
Value Chain



**Tanfac Industries Ltd.**

## Expansion through Inorganic Acquisition

### Acquired 2022

Products	12+
Plant	1
End Users	<ul style="list-style-type: none"> <li>• Refrigerants</li> <li>• Glass Etching</li> <li>• Solar Cells</li> <li>• Steel Surfacing</li> </ul>
Customers	105+

**Anupam Rasayan India Limited**

## Building blocks for growth

### 1986 onwards

Products	60+
Plants	6
End Users	<ul style="list-style-type: none"> <li>• Agrochemicals</li> <li>• Pharmaceuticals</li> <li>• Personal Care</li> <li>• Performance Materials</li> </ul>
Customers	70+

**Jayhawk Fine Chemicals**

## Global Expansion

### 2025 onwards

Products	20+
Plant	1
End Users	<ul style="list-style-type: none"> <li>• Life Science</li> <li>• Performance Materials</li> </ul>
Customers	10+

Anupam acquired ~26% stake in Tanfac for ~₹1,530Mn in May'22 at market cap of ₹5,950 Mn

Leading producer of RM - KF/HF



Producer of fluorinated intermediates



Manufacturer of niche molecules in fluorination chemistry

Tanfac

Anupam

Anupam




- **50 years old** specialty fluoride chemical manufacturer in India
- **Leading producer** of hydrofluoric acid (HF) and organic and inorganic fluorine-based products
- **Focused R&D** in niche & advanced fluorine derivatives over last 5 years

## Backward integration with Tanfac to secure KSM

- **Uninterrupted access** to key raw materials (HF and KF) for fluorination chemistry
- Enable **future expansion** of product series under fluorination chemistry
- **Reduce import dependence** on China
- **Increased capacities of existing product portfolio** of Tanfac through process improvement & debottlenecking
- **\$5+ Bn addressable market** of targeted Series for Anupam\*






## Tanfac Revenue Trend (₹ Crores)



Over the past 20 years, most new products in Agrochem, pharma, and polymers contain over 40% fluorine.



Anupam has acquired **Jayhawk Fine Chemicals LLC**, U.S.-based specialty chemicals company, at an **enterprise value of ~\$134Mn** (total purchase consideration of ~\$150Mn includes ~\$16Mn of cash & cash equivalents on Jayhawk's balance sheet) which will be **funded through combination of internal accruals, debt and quasi equity**

<b>Description, HQ &amp; Founding</b> 	<b>Manufactures performance materials</b> (~65%) & life / crop science molecules (~35%) <b>Founded in 1941, headquartered in Kansas, U.S.</b>
<b>Ownership</b> 	<b>Part of CABB Group</b>
<b>Key Financials (2026)</b> 	<ul style="list-style-type: none"> <li>• ~\$76Mn Revenue</li> <li>• ~\$15Mn EBITDA (~19% margins)</li> </ul>
<b>Business Model</b> 	Differentiated capabilities in <b>custom mfg. &amp; synthesis of niche, high-performance molecules</b> (leading portfolio of high value specialty chemicals) <b>Longstanding customer relationships</b> established with blue-chip customers
<b>Employees</b> 	~140 FTEs with majority of employees in operations



**~800 acres in the U.S.**  
with <10% utilized, offering strong expansion headroom

# Expanding Footprint In the USA Market

## Play in high value end markets

Expands access to fast-growing, innovation-led segments such as semiconductors, automotive / EV, aviation and electronics

## US-based platform for CDMO expansion

Offers a strategically valuable platform for Anupam to expand presence in the US and build a global CDMO network (in line with long-term expansion strategy)

## Facilitate sectoral diversification


Enables diversification beyond agrochem and pharma into high value, less cyclical segments like performance polymers and polyimides

## Complementary tech & integration advantage

Strong synergies via complementary tech – leveraging Jayhawk's high-purity tech with Anupam's backward integration capabilities to enable dual-site production and faster scale-up

## Access to strategic customer base

Strengthening access to leading global customers and opens new downstream opportunities



# Integrated Platform with Resilient Business Model

## Critical RM control



TANFAC

*(HF & KF production)*

HF

KF



## Differentiated material platforms



ANUPAM RASAYAN

*(Advanced intermediates)*

Fluorinated Intermediates

Aromatic Diamines

Non-Fluorinated Intermediates



Jayhawk Fine Chemicals

*(Synthesis & transformation)*

Aromatic Dianhydrides

Custom Synthesis



Polymers  
(Polyimides | Epoxies)

Electronic Chemicals  
(Semiconductor materials)

API / advance pharma intermediates

Crop Protection Actives / Intermediates

Electric Vehicles

## High value end markets



Pharmaceutical



Electronics



Defense



Others (aerosols, personal care)

Global footprint and combined capabilities supporting independent specialty manufacturing platform

# 04

Growth Drivers





# Expansion in Fluorination Chemistry

FOCUSED SEGMENTS	MOLECULES	END APPLICATION	CUSTOMER	SEGMENT REVENUE POTENTIAL
POLYMERS	PRODUCT A	ELASTOMER	US MNC	\$40 – 70 Mn.
	PRODUCT B	SEMICONDUCTOR/ FLAME RETARDANT	JAPANESE MNC	
PHARMACEUTICALS	PRODUCT X/Y	CARDIO/ANTI-VIRAL	INDIAN MNC	\$80 – 90 Mn.
	PRODUCT Z	ONCOLOGY	INDIAN MNC	
AGROCHEM	PRODUCT M	INSECTICIDE	GLOBAL MNC	\$100 Mn.
	PRODUCT N	HERBICIDE	EUROPEAN ORIGINATOR	

Anupam will source fluorinating agents (KF and HF) from Tanfac and manufacture **Value Added Products (VAPs) at Anupam**

All molecules in these series are high value high margin product

**For most of these products, Anupam will be single supplier out of Asia on exclusive basis to originators**

**\$5+ Bn**

Addressable market of Targeted Series for Anupam\*

**\$220 – \$260 Mn**

Revenue Potential for Anupam\*

\*Global Consulting Firm Research


## Pharma

New Strategic Custom Development Products under pipeline to be manufactured by Anupam in India:



- Import Substitute "Key Starting Materials"
- To manufacture KSM/intermediates for blockbuster molecules

## Polymer



- Key Intermediates for New Launch Active Ingredients which are currently being manufactured in Japan and US.
- Niche high end molecules

**65+**

Number of molecules of pharma and polymer in R&D and pilot

**10+**

Number of molecules in pharma and polymer commercialized in last 2 years

## STRENGTHS AND KEY HIGHLIGHTS



### Manufacturing Prowess

- Doubled manufacturing capacity in the last three years
- Strong capex plans to expand capacity into newer molecules / chemistries

### R&D Capabilities

- DSIR recognized R&D center with a team of 90+ R&D professionals
- Strong technical capabilities and robust R&D pipeline (90+ molecules)

### Strengthening Supply Chain

- Integration in Customer supply Chain
- Acquisition of Tanfac for backward integration
- Forward Integration through Jayhawk acquisition

### Sustainable Business Model

- Partner of choice for originators/leading MNC
- Multi pronged strategy leading to high growth



**Company Details:**



**ANUPAM RASAYAN INDIA LTD.**

**Anupam Rasayan Ltd.**

CIN – L24231GJ2003PLC042988

**Investor Relations Advisor :**

**SGA** Strategic Growth Advisors

**Strategic Growth Advisors Pvt. Ltd.**

CIN - U74140MH2010PTC204285

Mr. Shrikant Sangani / Ms. Shaily Patwa

Email - [shrikant.sangani@sgapl.net](mailto:shrikant.sangani@sgapl.net) / [shaily.p@sgapl.net](mailto:shaily.p@sgapl.net)

Mobile No – 9619595686 / 9819494608

[www.sgapl.net](http://www.sgapl.net)

**Thank You**